EADV 2025: Day 3 Recap

The third day of the European Academy of Dermatology and Venereology Congress is complete! Check out our day 3 recap below. To stay informed with the latest insights live from Paris, France, subscribe to receive our eNewsletters and follow Dermatology Times on LinkedIn, Facebook, and X.

Guttman-Yassky Showcases 2 Paths to Long-Term AD Control at EADV 2025

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader

The oral degrader produced biomarker reductions consistent with or superior to dupilumab.

Rocatinlimab Maintains Safety Profile in 24-Week AD Study

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

DELTA TEEN Trial Demonstrates Superiority of Delgocitinib Cream in Adolescents With Chronic Hand Eczema

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

Bunick Discusses Dual-Target Biologic at EADV 2025

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

APG777 Trial Demonstrates Efficacy, Safety in AD

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo.